Discounted Cash Flow (DCF) Analysis Unlevered
Anixa Biosciences, Inc. (ANIX)
$3.51
-0.18 (-4.88%)
All numbers are in Millions, Currency in USD
Operating Data
Year A/P | 2019 Actual | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected | 2028 Projected |
Revenue | 0.25 | - | - | - | - | - | - | - | - | - |
---|---|---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||||
EBITDA | -10.59 | - | - | - | - | - | - | - | - | - |
EBITDA (%) | ||||||||||
EBIT | -11.05 | - | - | - | - | - | - | - | - | - |
EBIT (%) | ||||||||||
Depreciation | 0.47 | - | - | - | - | - | - | - | - | - |
Depreciation (%) |
Balance Sheet Data
Year A/P | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Actual | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected | 2028 Projected |
Total Cash | 5.84 | - | - | - | - | - | - | - | - | - |
---|---|---|---|---|---|---|---|---|---|---|
Total Cash (%) | ||||||||||
Account Receivables | 0.07 | - | - | - | - | - | - | - | - | - |
Account Receivables (%) | ||||||||||
Inventories | -2.35 | - | - | - | - | - | - | - | - | - |
Inventories (%) | ||||||||||
Accounts Payable | 0.59 | - | - | - | - | - | - | - | - | - |
Accounts Payable (%) | ||||||||||
Capital Expenditure | -0.18 | - | - | - | - | - | - | - | - | - |
Capital Expenditure (%) |
Weighted Average Cost Of Capital
Share price | $ 3.51 |
---|---|
Beta | 0.857 |
Diluted Shares Outstanding | 30.98 |
Cost of Debt | |
Tax Rate | 1.20 |
After-tax Cost of Debt | 4.94% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 8.401 |
Total Debt | 0.17 |
Total Equity | 108.74 |
Total Capital | 108.91 |
Debt Weighting | 0.16 |
Equity Weighting | 99.84 |
Wacc |
Build Up Free Cash
Year A/P | 2019 Actual | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected | 2028 Projected |
Revenue | 0.25 | - | - | - | - | - | - | - | - | - |
---|---|---|---|---|---|---|---|---|---|---|
EBITDA | -10.59 | - | - | - | - | - | - | - | - | - |
EBIT | -11.05 | - | - | - | - | - | - | - | - | - |
Tax Rate | -1.49% | -0.40% | 1.38% | 2.03% | 1.20% | 0.55% | 0.55% | 0.55% | 0.55% | 0.55% |
EBIAT | -11.22 | - | - | - | - | - | - | - | - | - |
Depreciation | 0.47 | - | - | - | - | - | - | - | - | - |
Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
Inventories | - | - | - | - | - | - | - | - | - | - |
Accounts Payable | - | - | - | - | - | - | - | - | - | - |
Capital Expenditure | -0.18 | -0.02 | - | - | - | - | - | - | - | - |
UFCF | -10.93 | - | - | - | - | - | - | - | - | - |
WACC | ||||||||||
PV UFCF | - | - | - | - | - | - | - | - | - | |
SUM PV UFCF | - |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 8.40 |
Free cash flow (t + 1) | - |
Terminal Value | - |
Present Value of Terminal Value | - |
Intrinsic Value
Enterprise Value | - |
---|---|
Net Debt | -0.74 |
Equity Value | - |
Shares Outstanding | 30.98 |
Equity Value Per Share | - |